Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 14:4:212286.
doi: 10.7573/dic.212286. eCollection 2015.

Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder

Molly R Belkin  1 , Thomas L Schwartz  1
Affiliations
Review

Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder

Molly R Belkin et al. Drugs Context. .

Abstract

Clonidine and guanfacine are alpha-2 receptor agonists that decrease sympathetic outflow from the central nervous system. Posttraumatic stress disorder (PTSD) is an anxiety disorder that is theorized to be related to a hyperactive sympathetic nervous system. Currently, the only US Food and Drug Administration (FDA)-approved medications for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. Sometimes use of the SSRIs may not lead to full remission and symptoms of hyperarousal often persist. This article specifically reviews the literature on alpha-2 receptor agonist use for the treatment of PTSD and concludes that while the evidence base is limited, these agents might be considered useful when SSRIs fail to treat symptoms of agitation and hyperarousal in patients with PTSD.

Keywords: Adrenergic alpha-2 receptor agonists; anxiety disorders; clonidine; guanfacine; humans; posttraumatic; stress disorders; sympathetic nervous system; treatment outcome.

PubMed Disclaimer

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
    1. Sareen J. Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment. Can J Psychiatry. 2014;59:460–7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4168808&tool=p... [Last accessed: June 26th, 2015]. - PMC - PubMed
    1. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;4 doi: 10.1002/14651858.CD005473.pub2. No.: CD005473. - DOI - PubMed
    1. Van Liempt S, Vermetten E, Geuze E, Westenberg HGM. Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review. Int Clin Psychopharmacol. 2006;21:193–202. doi: 10.1097/00004850-200607000-00001. - DOI - PubMed
    1. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71:463–74. doi: 10.4088/jcp.07m03890yel. - DOI - PMC - PubMed